Lab21, Quidel Expand International Distribution Agreement
News Feb 11, 2014
Lab21 has expanded its existing agreement with Quidel Corporation, through its subsidiary, Microgen Bioproducts Limited. This expands on the previous agreement which has seen Lab21 distribute the QuickVue product range in the UK.
The AnDiaTec product range includes tests that aid in the diagnosis of several infectious diseases including Norovirus, Enterovirus, Epstein Barr Virus, Herpes Simplex, Varicella-Zoster Virus, Chlamydia and Mycobacterium tuberculosis. The previous agreement saw Lab21 distribute Quidel’s QuickVue products which included rapid diagnostics for Chlamydia, H. Pylori, Influenza, Respiratory Syncytial Virus, Streptococcus, and Pregnancy.
Graham Mullis, CEO of Lab21, commented: “We are delighted to expand our distribution partnership with Quidel to include the AnDiaTec molecular product portfolio. Having built a strong reputation in the provision of tests for infectious diseases, this deal will further expand the range of products we are able to offer, strengthening our position as experts in the provision of clinical diagnostics.”
John Garland, Senior Sales & Marketing Director EMEA, Quidel, commented: “Lab21 has a strong reputation in the provision of excellent clinical diagnostics products. Lab21’s expertise and network with its customer base will be crucial to encouraging the increased uptake of the rapid, accurate and easy to use AnDiaTec Product Range.”
Eagle-Eyed Machine Learning Algorithm Outdoes Human ExpertsNews
A new approach to machine learning enables AI to make the rules.READ MORE
First Practice Guidelines for Clinical Evaluation of Alzheimer's diseaseNews
Alzheimer’s disease experts gather in Chicago to plan guidelines for cliniciansREAD MORE